Nouryon, a global specialty chemicals leader, plans to invest in its Kromasil manufacturing facility in Bohus, Sweden, to meet the increasing global demand from the pharmaceutical and biotechnology industries for high-performing solutions. The investment is expected to double the facility’s existing production capacity, which will strengthen Nouryon’s global leadership position in high-performance silica.
“This investment reflects Nouryon’s commitment to be a trusted partner to the pharma and biotech industries, which increasingly rely on us to provide solutions that contribute to the production of safe pharmaceuticals,” said Johan Landfors, Executive Vice President and President, Technology Solutions and Europe at Nouryon.
Kromasil products are used by the pharmaceutical, food and beverage, clinical, and environmental industries for applications ranging from laboratory analysis to industrial-scale purification. Kromasil contributes to improved treatment of diabetes as a vital part of the purification of insulin. Other uses include complex bio-pharma applications.
"Bio-pharmaceuticals, such as peptides, proteins and hormones, are a growing market and we see an increase in demand worldwide, particularly from our customers in India, China and Southeast Asia,” said Patrick Wilhelm, Vice President of Inorganic Specialties at Nouryon. “This facility expansion will reinforce our leadership position in the global high-performance silica market targeted to the pharma and biotech industries, and it will allow us to meet the growing demand for our Kromasil products.”
Construction of the Nouryon facility expansion is scheduled to begin in 2022.
Nouryon is a leading producer of high-performance silica worldwide and has more than 30 years of expertise in spherical silica for analytical to process-scale liquid chromatography under the brand Kromasil. Kromasil chromatography resins offer superior separation performance leading to increased efficiency and decreased costs.
This investment follows Kromasil’s recently introduced efficient purification strategy for pharmaceuticals used for type 2 diabetes.
PureCycle’s First Plastic Recycling Plant in Europe located in Antwerp-Brugges NextGen District, Belgium
The new plant is expected to have an annual capacity of 59,000 metric tons, with opportunities to expand operations with an anticipated total capacity of approximately 240,000 metric tons per year.
CABB site in Kokkola, Finland: vital growth with a focus on sustainability
CABB Group will invest more than EUR 50 million by 2025 in expanding its facilities at its site in Kokkola, Finland. A new office building is also being constructed. Special attention is being pai...
TotalEnergies commissions BioBéarn, the country’s largest anaerobic digestion unit in Mourenx, France
The project will convert 220,000 metric tons of organic waste into 200,000 metric tons per year of digestate, a natural fertilizer, and 160 GWh of biomethane. This new unit allowing to avoid the em...
Borealis, committed to lead the transformation to a circular economy, acquires a majority stake in Renasci’s Ostend facility, Belgium
Borealis increases its financial investment in Renasci to acquire a majority shareholding position of 50.01%. Investment will provide Borealis increasing access to chemically recycled feedstock, st...